Get started
CLINUVEL PHARMACEUTICALS LTDCLINUVEL PHARMACEUTICALS LTDCLINUVEL PHARMACEUTICALS LTD

CLINUVEL PHARMACEUTICALS LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

UR9 chart


Full chart

UR9 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪365.88 M‬ EUR
Dividend yield (indicated)
0.39%
Price to earnings Ratio (TTM)
17.27
Basic EPS (TTM)
0.46 EUR
Net income (FY)
‪22.18 M‬ EUR
Revenue (FY)
‪54.88 M‬ EUR
Shares float
‪39.75 M‬
Beta (1Y)
1.01

About CLINUVEL PHARMACEUTICALS LIMITED


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lachlan Hay
Website
clinuvel.com
Headquarters
Melbourne
Founded
1999
ISIN
AU000000CUV3
FIGI
BBG00FGWG6T6
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Check out other big names from the same industry as UR9.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

UR9 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of UR9 is 6.93 EUR — it has decreased by −7.05% in the past 24 hours. Watch CLINUVEL PHARMACEUTICALS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CLINUVEL PHARMACEUTICALS LTD stocks are traded under the ticker UR9.
UR9 stock has risen by 4.06% compared to the previous week, the month change is a 24.22% rise, over the last year CLINUVEL PHARMACEUTICALS LTD has showed a −22.84% decrease.
We've gathered analysts' opinions on CLINUVEL PHARMACEUTICALS LTD future price: according to them, UR9 price has a max estimate of 22.37 EUR and a min estimate of 8.39 EUR. Watch UR9 chart and read a more detailed CLINUVEL PHARMACEUTICALS LTD stock forecast: see what analysts think of CLINUVEL PHARMACEUTICALS LTD and suggest that you do with its stocks.
UR9 reached its all-time high on Sep 23, 2021 with the price of 27.00 EUR, and its all-time low was 0.64 EUR and was reached on Dec 27, 2013. View more price dynamics on UR9 chart.
See other stocks reaching their highest and lowest prices.
UR9 stock is 9.24% volatile and has beta coefficient of 1.01. Track CLINUVEL PHARMACEUTICALS LTD stock price on the chart and check out the list of the most volatile stocks — is CLINUVEL PHARMACEUTICALS LTD there?
Today CLINUVEL PHARMACEUTICALS LTD has the market capitalization of ‪350.65 M‬, it has increased by 3.47% over the last week.
Yes, you can track CLINUVEL PHARMACEUTICALS LTD financials in yearly and quarterly reports right on TradingView.
CLINUVEL PHARMACEUTICALS LTD is going to release the next earnings report on Sep 2, 2025. Keep track of upcoming events with our Earnings Calendar.
UR9 earnings for the last half-year are 0.17 EUR per share, whereas the estimation was 0.13 EUR, resulting in a 29.03% surprise. The estimated earnings for the next half-year are 0.16 EUR per share. See more details about CLINUVEL PHARMACEUTICALS LTD earnings.
CLINUVEL PHARMACEUTICALS LTD revenue for the last half-year amounts to ‪21.30 M‬ EUR, despite the estimated figure of ‪20.74 M‬ EUR. In the next half-year revenue is expected to reach ‪34.41 M‬ EUR.
UR9 net income for the last half-year is ‪8.41 M‬ EUR, while the previous report showed ‪15.37 M‬ EUR of net income which accounts for −45.28% change. Track more CLINUVEL PHARMACEUTICALS LTD financial stats to get the full picture.
Yes, UR9 dividends are paid annually. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (TTM)% is 0.40%. Tracking CLINUVEL PHARMACEUTICALS LTD dividends might help you take more informed decisions.
CLINUVEL PHARMACEUTICALS LTD dividend yield was 0.33% in 2024, and payout ratio reached 6.99%. The year before the numbers were 0.28% and 8.07% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLINUVEL PHARMACEUTICALS LTD EBITDA is ‪28.50 M‬ EUR, and current EBITDA margin is 50.73%. See more stats in CLINUVEL PHARMACEUTICALS LTD financial statements.
Like other stocks, UR9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLINUVEL PHARMACEUTICALS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLINUVEL PHARMACEUTICALS LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLINUVEL PHARMACEUTICALS LTD stock shows the sell signal. See more of CLINUVEL PHARMACEUTICALS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.